Case report

Therapeutic use of intermittent fasting and ketogenic diet as an alternative treatment for type 2 diabetes in a normal weight woman: a 14-month case study

Charlene Lichtash 1, Jason Fung 2, Katherine Connor Ostoich 3, Megan Ramos 4

SUMMARY
This case demonstrates the effective and sustainable use of intermittent fasting (IF) and ketogenic diet (KD) in a normal weight patient with type 2 diabetes, who did not attain glycaemic control with a standard care approach. A 57-year-old woman with type 2 diabetes treated with metformin and strict adherence to a standard diabetic diet presented with a haemoglobin A1c (HbA1c) of 9.3%. Within 4 months of transitioning to KD, combined with IF, she achieved glycaemic control off pharmacotherapy, with HbA1c of 6.4. IF regimens started as 24 hours three times per week, followed by 42 hours three times per week, then 42 hours two times per week and 16 hours once per week. A maintenance phase was then begun at 8 months; IF was reduced to 16 hours per day, with 24 hours three times per month, and metformin was restarted. At 14 months, HbA1c reached 5.8%, and body mass index was minimally changed.

BACKGROUND
Diabetes mellitus type 2 is a disease characterised by hyperglycaemia, varying levels of insulin resistance and impaired pancreatic beta-cell function. Both genetic and environmental factors contribute to the pathogenesis of type 2 diabetes. 1 The growing epidemic of type 2 diabetes worldwide highlights the need for accessible preventative and therapeutic strategies. According to a global estimate by the WHO in 2014, an estimated 422 million adults were living with diabetes, with the prevalence of diabetes having doubled since 1980. 2 In 2012, diabetes was the eighth leading cause of death among both sexes and the fifth leading cause of death in women. 2

Standard approaches to the treatment of type 2 diabetes incorporate lifestyle management, pharmacotherapy and occasionally bariatric surgery. 3–5 The goal of treatment is euglycaemia and a reduction of the incidence of microvascular and macrovascular complications of type 2 diabetes. Medical nutrition therapy (MNT) is widely accepted as part of the standard of care in a diabetic patient. 4 Guidelines cite several diets, including the Mediterranean diet, the Dietary Approaches to Stop Hypertension diet, vegetarian diet and low-carbohydrate diet, as effective in lowering haemoglobin A1c (HbA1c). 4 However, there is no consensus on the ideal macronutrient composition of diet to achieve control or remission of type 2 diabetes. 4 Ketogenic diets (KDs), which induce a state of nutritional ketosis (defined in the medical literature as a blood beta-hydroxybutyrate level of 0.5–3.0 mmol/L), have demonstrated effective reduction in HbA1c and metabolic parameters in patients with type 2 diabetes; however, studies are limited in size and number. 6–8

Remission in type 2 diabetes has been demonstrated in large trials studying caloric restriction, as well as bariatric surgery. 8–11 While effective, bariatric surgery is limited by its accessibility, potential for complications and invasive nature. Caloric restriction is limited by long-term patient adherence. 12 Caloric restriction results in compensatory changes in the hormonal regulators of body weight, effectively reducing energy expenditure and increasing hunger. 12 These changes have been shown to persist for at least 12 months after implementing a calorie-restricted diet, explaining the challenge in applying this approach to the treatment of type 2 diabetes. 12

By contrast, intermittent fasting (IF) is emerging as a potentially sustainable strategy to achieve control or remission of type 2 diabetes. Fasting is the voluntary abstinence from food, and IF is an eating regimen by which all meals are consumed within a strictly defined window of time, followed by fasting. 13 Some available studies on IF use variations of fasting that allow for the ingestion of fewer calories during this window, while others abstain from caloric intake altogether. 13 Patterns and lengths of fasting also vary among studies. Studies on the therapeutic use of IF in type 2 diabetes are very limited. Herein, we present a case of a woman with type 2 diabetes who successfully used a combination of IF and a low-carbohydrate KD to achieve glycaemic control.

While reduction of body weight is typically the goal of IF regimens, not all patients who suffer from type 2 diabetes are overweight. Many cases of type 2 diabetes improve or remit with weight loss, but the two goals are not the same. In this case, a change in dietary pattern effectively controlled type 2 diabetes, although the patient was not overweight and overall weight change was minimal.

CASE PRESENTATION
A 57-year-old woman with a 15-year history of type 2 diabetes had been managed for the majority of her illness with metformin and a standard diabetic diet. She had a remote history of gestational diabetes at age 20 and 34 years. At the time of her diagnosis...
with type 2 diabetes mellitus at age 42 years, her HbA1c was 7.1% and body mass index (BMI) was 21.9 kg/m², classified as normal weight. During the course of her illness, she had strictly adhered to a diet prescribed to her by a registered dietician and based on prior American Diabetes Association (ADA) guidelines. It had consisted of carbohydrates from fruits, vegetables, whole grains, legumes and low-fat dairy, as well as poultry, fish and nuts. She had strictly limited her intake of saturated fat, red meats, sweets, sugarsweetened beverages and sodium. She had regularly eaten three meals per day with two snacks.

In June 2016, at age 54 years, her HbA1c had risen to 8.7% and BMI to 23.2 kg/m², while on metformin and her diabetic diet; glipizide was then added to her regimen. By February 2017, her HbA1c had only marginally improved to 8.3%, but she experienced weight gain with a rise in her BMI to 24%, a common side effect of sulfonylurea drugs. Pioglitazone was subsequently added to her regimen of metformin and glipizide, but she reported not taking it consistently due to episodes of hypoglycaemia and dizziness. In June 2017, her HbA1c was 7.8%, and she was told to lower her dose of glipizide, continue metformin and to resume pioglitazone. In October 2017, her HbA1c had improved to 6.5%; however, she reported frequent hypoglycaemia, dizziness and feeling unwell, and she discontinued her pioglitazone and glipizide on her own. In July 2018, her HbA1c had risen to 9.3% on a regimen of metformin and her diabetic diet.

TREATMENT

In July 2018, she began strictly following a KD, followed by the initiation of an IF regimen 2 weeks later. The KD, a low-carbohydrate high-fat (LCHF) diet, consisted of the following macronutrient composition: 80% fat, 15% protein and 5% carbohydrates. The diet focused on eating natural, unprocessed foods containing a variety of monounsaturated and polyunsaturated sources. Protein was predominantly from pasture-fats containing a variety of monounsaturated and polyunsaturated fats. The diet consisted of carbohydrates from fruits, vegetables, whole grains, legumes and low-fat dairy, as well as poultry, fish and nuts. She had strictly limited her intake of saturated fat, red meats, sweets, sugar-sweetened beverages and sodium. She had regularly eaten three meals per day with two snacks.

In an effort to test the need for continued 42 hours per day and 24 hours per day fasting, she drank water, plain tea or coffee and occasionally homemade bone broth.

In June 2016, at age 54 years, her HbA1c had risen to 8.7% and BMI to 23.2 kg/m², while on metformin and her diabetic diet; glipizide was then added to her regimen. By February 2017, her HbA1c had only marginally improved to 8.3%, but she experienced weight gain with a rise in her BMI to 24%, a common side effect of sulfonylurea drugs. Pioglitazone was subsequently added to her regimen of metformin and glipizide, but she reported not taking it consistently due to episodes of hypoglycaemia and dizziness. In June 2017, her HbA1c was 7.8%, and she was told to lower her dose of glipizide, continue metformin and to resume pioglitazone. In October 2017, her HbA1c had improved to 6.5%; however, she reported frequent hypoglycaemia, dizziness and feeling unwell, and she discontinued her pioglitazone and glipizide on her own. In July 2018, her HbA1c had risen to 9.3% on a regimen of metformin and her diabetic diet.

In an effort to test the need for continued 42 hours per day and 24 hours per day fasting, she drank water, plain tea or coffee and occasionally homemade bone broth.

OUTCOME AND FOLLOW-UP

Four weeks after initiating her dietary changes, the patient discontinued all medications, including metformin, an antihypertensive and a statin, while at the same time significantly improving glycaemic control. A timeline and summary of the patient’s diabetic medications with health parameters recorded at each visit are displayed in table 1. HbA1c dropped by 2.9%, from 9.3% to 6.4% during the first 4 months of dietary treatment, as depicted in figure 1. A few hypoglycemic episodes were noted only when initiating the IF regimen, but none subsequently. Her HbA1c at 8 months was 6.4%, at which time, fasting insulin, postprandial insulin rise and C peptide were all at the lower end of normal range. At this point, when glycaemic control had been achieved, metformin was added. At 14 months, HbA1c was reduced to 5.8. The patient's weight and BMI were mildly reduced, as demonstrated in figure 2, with her most recent weight and BMI being 6.4 54.9 22.1

| Date of visit | Treatment at time of visit | HbA1C (%) | Weight (kg) | BMI (kg/m²) |
|--------------|----------------------------|-----------|-------------|-------------|
| June 2016    | Metformin 1000 mg two times per day | 8.7       | 57.8        | 23.2        |
| February 2017| Metformin 1000 mg two times per day Glipizide 10 mg two times per day | 8.3       | 59.6        | 24.0        |
| June 2017    | Metformin 1000 mg two times per day Glipizide 10 mg two times per day Pioglitazone 15 mg/day (not taken consistently due to side effects) | 7.8       | 58.2        | 23.5        |
| October 2017 | Metformin 1000 mg two times per day Glipizide 10 mg/day, 5 mg nightly Pioglitazone 30 mg/day | 6.5       | 60.0        | 24.2        |
| July 2018    | Metformin 1000 mg two times per day | 9.3       | 55.3        | 22.3        |
| November 2018| Ketogenic diet Intermittent fasting | 6.4       | 51.7        | 20.9        |
| December 2018| Ketogenic diet Intermittent fasting | 6.1       | 52.6        | 21.2        |
| January 2019 | Ketogenic diet Intermittent fasting | 6.5       | 53.0        | 21.4        |
| February 2019| Ketogenic diet Intermittent fasting | 6.1       | 52.1        | 21.0        |
| March 2019   | Ketogenic diet Intermittent fasting | 6.4       | 54.9        | 22.1        |
| September 2019| Ketogenic diet Intermittent fasting Metformin 1000 mg two times per day | 5.8       | 53.5        | 21.6        |

BMI, body mass index; HbA1C, haemoglobin A1C.

Figure 1 Glycosylated haemoglobin prior to and during treatment with intermittent fasting and ketogenic diet. HbA1c, haemoglobin A1c.

Innovations in treatment

Table 1 Timeline of patient treatment modality for type 2 diabetes and measured health parameters
53.5 kg and 21.6 kg/m², respectively. When fasting, she recorded ketone levels at 0.5–1 mmol/L using a commercial blood ketone monitor, confirming nutritional ketosis. During the first 8 days after initiating KD, the patient reported mild fatigue and headache. These self-limited symptoms are common when starting a KD and are often referred to colloquially as keto flu. Thereafter, she reported no difficulties in maintaining the diet and fasting regimen, and she noted an improvement in her energy level, exercise tolerance and quality of life. Despite tolerating the 42 hours fasting periods without difficulty, she reported greater satisfaction with her fasting regimen in the maintenance phase, citing a greater sense of normalcy when able to engage in daily meals. The patient currently continues with her KD and IF, which she plans to maintain indefinitely.

We present a case of a normal weight patient with uncontrolled type 2 diabetes despite adherence to oral hypoglycemic medications and standard dietary advice, who successfully managed her condition using a relatively novel lifestyle approach, combining IF with a KD. The therapeutic benefits of IF and KD in the management of type 2 diabetes are reported in the medical literature, but they have not been studied in large scale. Their use is guided predominantly by an understanding of their proposed pathophysiologic mechanisms reported in animal data, and by outcomes reported in limited human data.

Studies on IF generally demonstrate its effectiveness in improving glycaemic control and other metabolic parameters, including reduction in visceral fat, blood pressure and markers of oxidative stress and inflammation. The available human data for IF show marked benefit in pre-diabetes and type 2 diabetes. In a case report of three patients with long-standing type 2 diabetes each requiring at least 70 units of insulin per day, the implementation of 24 hours fasting periods either three times per week or on alternate days, combined with a recommended low-carbohydrate diet resulted in the complete discontinuation of insulin in all three patients; reductions in HbA1c, BMI and waist circumference were also demonstrated. Moreover, the benefits of IF on insulin sensitivity extend beyond its influence on weight loss. A recent trial in men with pre-diabetes and overweight or obesity showed that 5 weeks of an IF regimen improved insulin sensitivity and pancreatic beta-cell responsiveness, independent of weight loss. Another study comparing caloric restriction to an IF regimen for weight loss showed a greater increase in insulin sensitivity when using an IF strategy. The findings in our case mirror those in the literature; IF was an effective and sustainable tool for achieving glycaemic control and reducing the need for pharmacotherapy in our patient, independent of weight loss.

Animal data propose a mechanistic understanding of the effects of IF on glycaemic control, providing hope that this treatment modality may slow or reverse the progression of type 2 diabetes. Mice fed a fasting-mimicking diet showed an increase in the proliferation and number of insulin-generating pancreatic beta cells in late-stage type 2 diabetes. Differentiated cells in the pancreas first decreased in number in the fasted state, and then pancreatic transitional cells and beta cells proliferated in the refed state. This study suggests that the therapeutic benefit of IF lies in the combined physiologic effects caused by both the fasted state, and by the recovery period during the feeding phase, to promote beta-cell repair. Another study in mice showed increased pancreatic beta-cell mass using IF. Glucose stimulated insulin secretion increased and beta-cell apoptosis decreased. Additionally, weight loss was not required for the benefits of IF on pancreatic beta-cell survival and function. The possibility that IF can promote pancreatic beta cells to regenerate and has the potential to revolutionise our treatment of type 2 diabetes, currently viewed as a chronic progressive disease. Further human studies are needed to help illuminate the potential role IF may have in slowing or reversing this disease.

The processes linking IF and benefits in insulin sensitivity are currently being studied to help with targeted pharmacologic therapy that can mimic effects of IF. One such area of ongoing research is in the sirtuin proteins, a family of enzymes with regulatory effects on glucose homeostasis, fat metabolism and life span regulated by both nutrient levels and calorie restriction. In particular, sirtuin-6 (SIRT6) is currently being studied as a potential therapeutic target for treating insulin resistance. SIRT6 in animal studies enhances insulin sensitivity and thereby decreases fasting blood glucose levels. Both short-term fasting and long-term calorie restriction increase SIRT6 levels in animal data further highlighting the role IF may play in disease modification.

Carbohydrate restriction is considered an effective treatment of type 2 diabetes in standard MNT, as defined by the ADA and the European Association for the Study of Diabetes. This approach even predates the development of exogenous insulin treatment in 1921, and is based on the fact that carbohydrates are the macronutrient with the highest glycaemic and insulin indices. An increased carbohydrate intake worsens markers of insulin resistance, such as postprandial glucose and insulin levels. Several trials have demonstrated improvements in HbA1c and insulin sensitivity when implementing a low-carbohydrate diet. The benefits of dietary carbohydrate restriction on control of blood glucose do not necessarily require weight loss, and low-carbohydrate diets have been shown to be generally well tolerated.

While the benefits of low-carbohydrate diets in type 2 diabetes are well accepted, the role of KD in the management of type 2 diabetes is not widely accepted at the present time, partly due to limited long-term safety data. A KD is typically defined as a LCHF diet that induces a shift in energy source from glucose to fatty acids and fatty-acid-derived ketones. Achieving nutritional ketosis has been shown to result in diabetes remission and reversal in some cases. A non-randomised long-term study implementing KD found significant improvements in biomarkers, including HbA1c, weight, fasting glucose, fasting insulin, blood pressure, cholesterol profile, high sensitivity C-reactive protein and a reduced need for type 2 diabetic medication. By contrast, the control arm consisting of patients with type 2 diabetes receiving ‘usual care’ with counselling on lifestyle interventions by a registered dietitian showed no significant change in any of the biomarkers measured.

Figure 2 Weight and body mass index during treatment with intermittent fasting and ketogenic diet. BMI, body mass index.

Lichtash C, et al. BMJ Case Rep 2020;13:e234223. doi:10.1136/bcr-2019-234223
Learning points

- The use of intermittent fasting (IF) and a ketogenic diet (KD) is an effective and sustainable alternative to a standard care approach in the treatment of type 2 diabetes.

- IF and KD can be used in a patient with type 2 diabetes who is normal weight. Glycaemic control can be achieved without resulting in significant weight loss.

- The use of this dietary strategy minimises or eliminates the need for pharmacotherapy, and it may be superior to a standard care approach to type 2 diabetes.

- We demonstrate good adherence to a strategy of IF and a KD in a patient who could not tolerate the adverse effects of additional oral hypoglycemic medications when under a standard care approach.
Innovations in treatment

14 American Diabetes Association, Bantle JP, Wylie-Rosett J, et al. Nutrition recommendations and interventions for diabetes: a position statement of the American diabetes association. *Diabetes Care* 2008;31 Suppl 1:S56–78.

15 de Cabo R, Mattson MP. Effects of intermittent fasting on health, aging, and disease. *N Engl J Med* 2019;381:2541–51.

16 Ding H, Zheng S, Garcia-Ruiz D, et al. Fasting induces a subcutaneous-to-visceral fat switch mediated by microRNA-149-3p and suppression of PRDM16. *Nat Commun* 2016;7:11533.

17 Furmli S, Elmasry R, Ramos M, et al. Therapeutic use of intermittent fasting for people with type 2 diabetes as an alternative to insulin. *BMJ Case Rep* 2018;10.1136/bcr-2017-221854. [Epub ahead of print: 09 Oct 2018].

18 Kanfi Y, Peshri V, Gozan YM, et al. Regulation of SIRT1 protein levels by nutrient availability. *FEBS Lett* 2008;582:2417–23.

19 Kanfi Y, Shalman R, Peshri V, et al. Regulation of SIRT6 protein levels by nutrient availability. *FEBS Lett* 2008;582:543–8.

20 Sutton EF, Beijl R, Early KS, et al. Early Time-Restricted feeding improves insulin sensitivity, blood pressure, and oxidative stress even without weight loss in men with prediabetes. *Cell Metab* 2019;27:1212–21.

21 Harvie MN, Pegington M, Mattson MP, et al. The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. *Int J Obes* 2011;35:714–27.

22 Cheng C-W, Villani V, Buono R, et al. Fasting-Mimicking diet promotes Ngn3-Driven β-cell regeneration to reverse diabetes. *Cell* 2017;168:775–88.

23 Liu H, Javaheri A, Godar RJ, et al. Intermittent fasting preserves beta-cell mass in obesity-induced diabetes via the autophagy-lysosome pathway. *Autophagy* 2017;13:1952–68.

24 Tang W, Fan Y. Sirt6 as a potential target for treating insulin resistance. *Life Sci* 2019;231:116558.

25 Qin K, Zhang N, Zhang Z, et al. SIRT6-mediated transcriptional suppression of Txnip is critical for pancreatic beta cell function and survival in mice. *Diabetologia* 2018;61:906–18.

26 Kanfi Y, Peshri V, Gil R, et al. Sirt6 protects against pathological damage caused by diet-induced obesity. *Aging Cell* 2010;9:162–73.

27 Westman EC, Yancy WS, Humphreys M. Dietary treatment of diabetes mellitus in the pre-insulin era (1914-1922). *Perspect Biol Med* 2006;49:77–83.

28 Kodama S, Saito K, Tanaka S, et al. Influence of fat and carbohydrate proportions on the metabolic profile in patients with type 2 diabetes: a meta-analysis. *Diabetes Care* 2009;32:959–65.

29 Wheeler ML, Dunbar SA, Jaacks LM, et al. Macronutrients, food groups, and eating patterns in the management of diabetes: a systematic review of the literature, 2010. *Diabetes Care* 2012;35:434–45.

30 Nickols-Richardson SM, Coleman MD, Volpe JJ, et al. Perceived hunger is lower and weight loss is greater in overweight premenopausal women consuming a low-carbohydrate/high-protein vs high-carbohydrate/low-fat diet. *J Am Diet Assoc* 2005;105:1433–7.

31 Gannon MC, Nuttall FQ. Control of blood glucose in type 2 diabetes without weight loss by modification of diet composition. *Nutr Metab* 2006;3:16.

32 D’Andrea Meira I, Romão TT, Pires do Prado HI, et al. Ketogenic diet and epilepsy: what we know so far. *Front Neurosci* 2019;13:5.

33 Hippocrates. On the sacred disease 400 BCE. Available: http://classics.mit.edu/Hippocrates/sacred.html

34 Bostock ECS, Kirkby KC, Taylor BV, et al. Consumer Reports of “Keto Flu” Associated With the Ketogenic Diet. *Front Nutr* 2020;7:20.